Credit rating agency, CARE has downgraded Rs 263.57 crore long term bank facilities of Parenteral Drugs (India) to ‘BBB-’ from ‘BBB+’. The rating agency has also downgraded Rs 45 crore short term bank facilities of the company to ‘A3’ from ‘A2’.
The revision in the ratings takes into account the recent investigations related to supply of contaminated IV fluids manufactured by the company which had an adverse impact on the company’s operations and financial profile.
Parenteral Drugs is one of the largest manufacturers of Intravenous (IV) Fluids in India. Its two wholly-owned subsidiaries, Punjab Formulations (Rated: CARE BBB-; PR3) and Goa Formulations (GFL; Rated CARE BBB-(SO); PR3 (SO) are also into manufacturing of IV Fluids. The group has a combined IV Fluid capacity of 3,300 lakh units/year and its facilities are located in Indore, Jalandhar and Goa.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.20 |
| Dr. Reddys Lab | 1295.00 |
| Cipla | 1322.70 |
| Zydus Lifesciences | 948.00 |
| Lupin | 2278.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: